NLS Pharmaceutics Increases Share Capital
Ticker: NCEL · Form: 6-K · Filed: Sep 25, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-increase, corporate-action, shares
TL;DR
NLS Pharma is boosting its share capital to CHF 937,600 effective Sept 27th via new share issuance.
AI Summary
NLS Pharmaceutics Ltd. announced on September 25, 2024, that it will file Amended and Restated Articles of Association to reflect an increase in share capital. This change, effective September 27, 2024, will result in a total outstanding share capital of CHF 937,600, achieved through the issuance of 87,369.55 registered shares.
Why It Matters
This filing indicates a capital raise or restructuring, which could impact the company's financial position and future growth prospects.
Risk Assessment
Risk Level: low — The filing is a routine corporate action related to share capital and does not present immediate financial or operational risks.
Key Numbers
- CHF 937,600 — New Share Capital (Total outstanding share capital effective September 27, 2024.)
- 87,369.55 — New Shares Issued (Number of registered shares issued to increase capital.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- CHF 937,600 (dollar_amount) — Total outstanding share capital after amendment
- September 27, 2024 (date) — Effective date of share capital increase
- 87,369.55 (dollar_amount) — Number of registered shares issued
FAQ
What is the purpose of the Amended and Restated Articles of Association?
The Amended and Restated Articles of Association are being filed to reflect the increase of the company's new share capital.
When will the increase in share capital become effective?
The increase in share capital will be effective as of September 27, 2024.
What will be the total outstanding share capital after the amendment?
The total outstanding share capital will be CHF 937,600.
How many new registered shares are being issued?
87,369.55 registered shares are being issued.
Where is NLS Pharmaceutics Ltd. located?
NLS Pharmaceutics Ltd. is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-25 08:13:08
Filing Documents
- ea0215301-6k_nlspharma.htm (6-K) — 15KB
- ea021530101ex99-1_nlspharma.htm (EX-99.1) — 206KB
- ea021530101ex99-2_nlspharma.htm (EX-99.2) — 8KB
- 0001213900-24-081588.txt ( ) — 229KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 25, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2